Last reviewed · How we verify

Atezolizumab plus Tiraglolumab

Grupo Espanol Multidisciplinario del Cancer Digestivo · Phase 2 active Small molecule

Atezolizumab plus Tiraglolumab is a PD-1/PD-L1 inhibitor and TIGIT inhibitor Small molecule drug developed by Grupo Espanol Multidisciplinario del Cancer Digestivo. It is currently in Phase 2 development for Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors.

Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways.

Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways. Used for Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors.

At a glance

Generic nameAtezolizumab plus Tiraglolumab
SponsorGrupo Espanol Multidisciplinario del Cancer Digestivo
Drug classPD-1/PD-L1 inhibitor and TIGIT inhibitor
TargetPD-L1 and TIGIT
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

By blocking these interactions, Atezolizumab and Tiraglolumab aim to enhance the body's immune response against cancer cells. This is achieved by preventing the cancer cells from evading the immune system's attack. The combination of these two drugs may lead to a more effective anti-tumor response.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atezolizumab plus Tiraglolumab

What is Atezolizumab plus Tiraglolumab?

Atezolizumab plus Tiraglolumab is a PD-1/PD-L1 inhibitor and TIGIT inhibitor drug developed by Grupo Espanol Multidisciplinario del Cancer Digestivo, indicated for Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors.

How does Atezolizumab plus Tiraglolumab work?

Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways.

What is Atezolizumab plus Tiraglolumab used for?

Atezolizumab plus Tiraglolumab is indicated for Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors.

Who makes Atezolizumab plus Tiraglolumab?

Atezolizumab plus Tiraglolumab is developed by Grupo Espanol Multidisciplinario del Cancer Digestivo (see full Grupo Espanol Multidisciplinario del Cancer Digestivo pipeline at /company/grupo-espanol-multidisciplinario-del-cancer-digestivo).

What drug class is Atezolizumab plus Tiraglolumab in?

Atezolizumab plus Tiraglolumab belongs to the PD-1/PD-L1 inhibitor and TIGIT inhibitor class. See all PD-1/PD-L1 inhibitor and TIGIT inhibitor drugs at /class/pd-1-pd-l1-inhibitor-and-tigit-inhibitor.

What development phase is Atezolizumab plus Tiraglolumab in?

Atezolizumab plus Tiraglolumab is in Phase 2.

What are the side effects of Atezolizumab plus Tiraglolumab?

Common side effects of Atezolizumab plus Tiraglolumab include Fatigue, Nausea, Diarrhea, Rash, Pyrexia.

What does Atezolizumab plus Tiraglolumab target?

Atezolizumab plus Tiraglolumab targets PD-L1 and TIGIT and is a PD-1/PD-L1 inhibitor and TIGIT inhibitor.

Related